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Abstract: INTRODUCTION: The brain-derived neurotrophic factor (BDNF) 
interacts with important genetic Alzheimer's disease (AD) risk factors. 
Specifically, variants within the SORL1 gene determine BDNF's ability to 
reduce Aβ in vitro. We sought to test whether functional BDNF variation 
interacts with SORL1 genotypes to influence expression and downstream AD-
related processes in humans. 
METHODS: We analyzed postmortem brain RNA-sequencing and 
neuropathological data for 441 subjects from the Religious Orders 
Study/Memory and Aging Project, and molecular and structural neuroimaging 
data for 1 285 subjects from the Alzheimer's Disease Neuroimaging 
Initiative. 
RESULTS: We found one SORL1 RNA transcript strongly regulated by SORL1-
BDNF interactions in elderly without pathological AD, and showing 
stronger associations with diffuse than neuritic Aβ plaques. The same 
SORL1-BDNF interactions also significantly influenced Aβ load as measured 
with [18F]Florbetapir PET.  
DISCUSSION: Our results bridge the gap between risk and resilience 
factors for AD, demonstrating interdependent roles of established SORL1 
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We are pleased to re-submit our revised manuscript entitled “Genetic Epistasis Regulates Amyloid 
Deposition in Resilient Aging” for publication in Alzheimer’s & Dementia. We have made changes in 
accordance with the editor’s suggestion, and the limitations section of our discussion has been 
enhanced as a result. 
 
Again, we greatly appreciate the time taken by editors and reviewers to re-evaluate our manuscript, and 
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revised cover letter (revision 2)
Response to Editor 
 
“Please incorporate your response to Reviewer #1 into the discussion, perhaps in the paragraph that 
describes the limitations.   2-4 sentences should suffice and read like, "it has been suggested...(reviewer 
#1 comments)".  "Unfortunately...(your response)."  And the third (or fourth) sentence should propose 
some future research/experiments to address this limitation.” 
 
As requested, we have incorporated a brief summary of this exchange regarding the 
measurements of SORL1 proteins as a limitation in our paper’s discussion: 
(Pg. 15, paragraph 2): “Finally, we acknowledge that mRNA levels of SORL1 may not be reliable 
indicators of protein levels. Unfortunately, we did not measure protein directly in our 
experiments. Future studies will need to measure protein directly in the tissues.  In fact, 
proteomic projects are currently underway in the ROS/MAP cohort that will include both SORL1 
and BDNF. However, there are also limitations to targeted proteomics; for example, it cannot 
capture individual post-translational modifications. Thus, ultimately, a variety of approaches, 
including the mRNA approach used in the present study, are useful for identifying genes and 
proteins important in the pathogenesis of AD.” 
 
Again, we thank the editor for their time and consideration. 
 
 
Response to editor comment (revision 2)
Research in Context 
 
Systematic review: Authors reviewed relevant literature using traditional sources (e.g., Pubmed) and 
meeting abstracts and presentations. SORL1 is a major risk factor for Alzheimer’s disease and several 
studies have demonstrated its interactions with other genes and proteins within neuroplastic and 
canonical Alzheimer’s-related pathways. 
Interpretation: We demonstrate that there is a genetic interaction between SORL1 and BDNF that 
influences SORL1 isoform expression and amyloid deposition both postmortem and in vivo. This result is 
convergent with previous reports of SORL1-dependent aspects of Alzheimer’s disease biology. 
Future directions: We find that one SORL1 isoform, SORL1-005, is an interactively regulated transcript 
and should be a focus of future studies. In addition, the relative impact of SORL1- and BDNF-related 
mechanisms on diffuse and neuritic amyloid accumulation should be explored further. 
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 BDNF Val66Met interacts with SORL1 variants to impact expression of SORL1-005. 
 SORL1-005 may influence diffuse rather than neuritic amyloid pathology in postmortem brain. 
 The BDNF-SORL1 interaction effect is present in individuals without confirmed Alzheimer’s 
disease. 







































































INTRODUCTION: The brain-derived neurotrophic factor (BDNF) interacts with important genetic 
Alzheimer’s disease (AD) risk factors. Specifically, variants within the SORL1 gene determine BDNF’s 
ability to reduce Aβ in vitro. We sought to test whether functional BDNF variation interacts with SORL1 
genotypes to influence expression and downstream AD-related processes in humans. 
METHODS: We analyzed postmortem brain RNA-sequencing and neuropathological data for 441 
subjects from the Religious Orders Study/Memory and Aging Project, and molecular and structural 
neuroimaging data for 1 285 subjects from the Alzheimer’s Disease Neuroimaging Initiative. 
RESULTS: We found one SORL1 RNA transcript strongly regulated by SORL1-BDNF interactions in elderly 
without pathological AD, and showing stronger associations with diffuse than neuritic Aβ plaques. The 
same SORL1-BDNF interactions also significantly influenced Aβ load as measured with [18F]Florbetapir 
PET.  
DISCUSSION: Our results bridge the gap between risk and resilience factors for AD, demonstrating 
interdependent roles of established SORL1 and BDNF functional genotypes. 
 





































































Genetic epistasis may be a major contributor to the “missing heritability” of late-onset Alzheimer’s 
disease (AD) [1], and recent efforts have demonstrated the importance of evaluating gene-gene 
interactions among AD risk variants using integrative approaches [2]. Variants within the sortilin-related 
receptor (SORL1, SORLA, LR11) gene are among the most highly-replicated genetic risk factors for late-
onset Alzheimer’s disease (AD); they have been associated with AD diagnosis in candidate studies [3], 
genome-wide association studies [4], and meta-analyses [5]. While studies have implicated SORL1 
genotypes independently in gene expression [6], the transcriptional control of SORL1 also depends on 
extragenous factors, particularly levels of the brain-derived neurotrophic factor (BDNF) [7]. Accordingly, 
it was recently shown that BDNF administration in iPSC-derived neuron cultures up-regulates SORL1 
expression in a SORL1-genotype dependent manner [8]. The BDNF Val66Met polymorphism determines 
the activity-dependent secretion of BDNF [9] and also the function of the BDNF pro-peptide in 
facilitating neuroplasticity (LTD) [10]. As such, BDNF Val66Met may serve as a functional assay for BDNF 
activity in the brain. Effects of BDNF Val66Met have been shown on early AD phenotypes, such as 
structural [11] and functional [12] neuroimaging, and cognition [13]. These effects may be downstream 
consequences of BDNF’s stimulation of SORL1 activity [14], and therefore may be subject to modulation 
by both BDNF and SORL1 genotypes interdependently. Studying the interaction of functional BDNF and 
SORL1 genotypes in large, well-characterized samples may provide insight into the nature of this 
transcriptional regulatory mechanism and risk vs. resilience for AD. 
We have previously shown a main effect of SORL1 genotype on levels of prefrontal SORL1 mRNA in 
postmortem brain [15] using microarray technology that was unable to detect specific SORL1 transcript 
isoforms. Since previous reports show differential SORL1 transcript expression both in AD [16] and as a 
result of SORL1 genotype [6], microarray analyses may have missed crucial transcript-specific 




































































it allows for the alignment of assembled transcript reads to any sequence template and the estimation 
of isoform expression based on these reads. We have also previously shown age-dependent effects of 
the BDNF Val66Met polymorphism on white matter microstructure, cortical thickness, and episodic 
memory performance in healthy adults [17], suggesting that as-of-yet unidentified factors may act to 
influence BDNF’s protective effects on neurodegeneration and cognitive aging. 
Given the regulatory interaction of BDNF protein with SORL1 genotype in human iPSC-derived neurons 
[8], we hypothesized that common SORL1 gene variants may interact with BDNF Val66Met to influence 
the expression of SORL1 transcripts. Further, given the functions of SORL1 within the amyloidogenic 
cascade, we hypothesized that genetic interactions predicting altered SORL1 expression may affect 
amyloid neuropathology as well as brain structures at risk in the early stages of AD. To test this, we 
performed an unbiased locus-wide gene-gene interaction analysis of SORL1 SNPs with BDNF Val66Met 
to model the expression of multiple SORL1 transcripts, quantified by RNA-seq of postmortem brain 
tissue, in 441 subjects from the Religious Orders Study and Memory and Aging Project (ROS/MAP). 
Transcripts showing significant evidence for regulation by SORL1-BDNF interactions were also tested for 
effects on postmortem neuropathology in the same subjects. We then tested significant SNP-SNP 
interactions for effects on in vivo frontal amyloid load, as measured by [18F]Florbetapir PET, in 710 
subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Finally, to explore potential 
downstream effects of these SNP-SNP interactions on brain structure, we examined 1 285 subjects from 
ADNI and 172 subjects from ROS/MAP with MRI estimates of entorhinal cortex volume, and 185 subjects 






































































2.1 Religious Orders Study and Memory and Aging Project (ROS/MAP) 
2.1.1 Study Participants 
A total of 441 subjects with genomic, RNA sequencing, and neuropathological data were included in the 
present study. All participants were from ROS [18] and MAP [18]; two large ongoing cohort studies 
enrolling non-AD subjects at baseline, centered at the Rush Alzheimer’s Disease Center at Rush 
University in Chicago, IL. Both studies were approved by the Institutional Review Board of Rush 
University Medical Center.  
2.1.2 Genetics 
Genotyping of all subjects was performed using the Affymetrix (Santa Clara, CA, USA) Genechip 6.0 
platform. APOE (rs7412 and rs429358) genotypes were imputed from MACH (version 1.0.16a) and 
HapMap release 22 CEU (build 36), as previously described [19]. Common variants within 10kb of the 
SORL1 locus (chr. 11, position 121,312,912 – 121,514,471; GRCh37 coordinates) were extracted using 
PLINK (v1.90b) [20]. Variants were pruned for minor allele frequency (MAF>0.1) and Hardy-Weinberg 
Equilibrium (HWE p>0.001), resulting in a final set of 160 for analysis.  
2.1.3 Postmortem SORL1 Isoform Expression 
RNA-seq data (50 million paired-end reads of 101 bp) were generated from frozen dorsolateral 
prefrontal cortex tissues following the construction of complementary DNA libraries, as previously 
published [21]. Expression abundance was calculated as fragments per kilobase of exon per million reads 
mapped (FPKM) (See Supplementary Methods). 
2.1.4 Postmortem Neuropathology 
A board-certified neuropathologist blinded to age and all clinical data established neuropathologic 




































































mid-frontal neuritic plaques and diffuse plaques, total amyloid, paired helical filament tau, and 
neurofibrillary tangles (see supplementary Methods). 
2.1.5 In Vivo Structural MRI 
High resolution structural T1 images were acquired for a subset of n=172 ROS/MAP subjects (overlap of 
n=5 with subjects from expression dataset) [22] and entorhinal cortex volumes (mm3) were estimated 
for each subject using Freesurfer (http://surfer.nmr.mgh.harvard.edu) (see Supplementary Methods). 
 
2.2 Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
2.2.1 Study Participants 
The Alzheimer’s Disease Neuroimaging Initiative (ADNI; phases 1, GO, and 2 – see Supplementary 
Methods) is a multi-center collaboration enrolling elderly subjects at various stages of cognitive 
impairment. All subjects are administered clinical evaluations at time of study enrollment by trained 
physicians as previously described [23]. See supplementary Methods for details. 
2.2.2 Genetics 
ADNI subjects were genotyped using the HumanOmniExpress BeadChip (Illumina Inc., San Diego, CA). 
Genetic quality control was conducted using PLINK (v1.90b). Imputation was performed using IMPUTE2 
(v2.3.1) [24], with the 1000 Genomes Phase1 integrated haplotypes as the reference panel. SNPs with 
an IMPUTE2 info score of less than 0.5, HWE p<0.001, and MAF <0.01 were excluded from further 
analyses.  
2.2.3 In Vivo Structural MRI and DTI 
A total of 1 285 subjects from ADNI 1, GO, and 2 underwent structural MRI protocols to generate 
estimates of entorhinal cortex volume. Entorhinal cortex and total intracranial volumes were estimated 
using FreeSurfer (v4.3) [25]. Diffusion-weighted images were acquired for a subset of 185 subjects from 




































































(FA) were generated for specific white matter tracts according to the JHU “Eve” white matter atlas labels 
(see Supplementary Methods).  
2.2.4 In Vivo Aβ [18F]Florbetapir PET 
PET imaging data were available for 710 subjects from ADNI 2. Details of brain Aβ [18F]Florbetapir PET 
imaging and preprocessing in ADNI have been described elsewhere [27]. Signal from [18F]Florbetapir 
within cortical subregions were not standardized and so we co-varied for signal from a composite 
reference region (see Supplementary Methods). 
 
2.3 Statistical Analysis 
Analyses were performed using R (v3.1.1) statistical software (http://www.r-project.org/) [28]. 
Haploview (v4.2) [29] was used for calculations of LD structure. Based on lack of expression, data for 
three transcripts could not be analyzed: SORL1-003, SORL1-004, SORL1-007 (See Figure S1 for size and 
position of all transcripts). All 10 remaining transcripts showed heavily right-skewed FPKM distributions 
(skewness ranging from 0.71-5.3, all D’Agostino test p<1.3x10-5) that could not be coerced to normal 
(using Box-Cox power transformations) and thus were evaluated as binary outcomes (expressed above 0 
FPKM vs. 0 FPKM, or median split where the median>0). Each of 160 SNPs within the SORL1 locus were 
tested for interaction with BDNF Val66Met, with each transcript as outcome using logistic regression, 
co-varying for technical and demographic factors. 
To correct for multiple testing accounting for LD structure across SORL1 SNPs, we first calculated the 
effective number of independent SNPs across the SORL1 locus (as in Replogle et al. [30]); of the 160 
SORL1 tested, six independent SNPs captured the haplotypic diversity at this locus (strong LD structure 
shown in Figure S2). Considering 10 SORL1 transcripts, the final experiment-wise Bonferroni corrected 




































































Transcripts that showed significant evidence for interactive regulation by SORL1 variants and BDNF 
Val66Met were analyzed for effects on neuropathology. Pathology levels were square-root transformed 
and analyzed using linear regression, and, since SORL1-005 expression was evaluated as a continuous 
predictor, influential observations (evaluated using dfbetas and Cook’s distance) were removed from 
these analyses (final n=439).  
SNP-SNP interactions from expression analyses that remained significant after correction for multiple 
testing were carried forward to test for effects on in vivo Aβ [18F]Florbetapir PET. To maintain regional 
specificity, average amyloid loads across seven bilateral frontal cortical regions of interest were analyzed 
as outcomes for each gene-gene interaction using linear regression. Interaction p-values were corrected 
for multiple testing using the False Discovery Rate (FDR) procedure (q=0.05).  
Finally, to examine potential downstream consequences of altered amyloid pathology on brain 
structure, the same set of SNP-SNP interactions identified by expression analyses were explored for 
effects on entorhinal cortex volume (one of the earliest brain regions to be affected by AD pathological 
lesions and atrophy [31]), and white matter FA across five bilateral tracts. 







































































3.1 SORL1 Transcript Expression and Postmortem Neuropathology 
Sample demographics for ROS/MAP are summarized in Table 1. Out of a total 1 600 tests, 36 remained 
significant after correction for multiple testing and all of these 36 modeled the same transcript, SORL1-
005 (ENST00000534286), as the outcome (Figure 1). The SNP showing the strongest interaction effect 
with BDNF Val66Met was rs12364988 (Wald X21=19.09, p=1.25x10
-5, n=441), where the rs12364988T 
allele reduced likelihood of SORL1-005 expression in the BDNFVal homozygotes (ORTT:CC=0.38, 
C.I.95%=[0.18,0.80]), but greatly increased likelihood of expression among BDNF
Met carriers (ORTT:CC=7.03, 
C.I.95%=[2.42,20.46]) (see Figure 2A). Rs12364988, within the 5’ region of SORL1, was in moderate to 
strong linkage disequilibrium (LD) with the remaining 35 SNPs that showed significant interaction with 
BDNF Val66Met in the ROS/MAP sample (D’ range=0.80-1, r2 range=0.35-1).  
Post-hoc tests in diagnostic subgroups revealed different patterns of effect in non-AD vs. pathologically-
confirmed AD subjects. In the non-AD subgroup (n=179), 44 tests showed interaction p-values below our 
threshold for multiple testing. As in the overall sample, all significant models predicted SORL1-005 
expression as outcome, though with much stronger effect sizes observed for the top interacting SORL1 
SNP (rs676759, Wald X21=19.27, p=1.14x10
-5) in the BDNFVal homozygote (ORCC:TT=0.093, 
C.I.95%=[0.026,0.34]) and BDNF
Met carrier groups (ORCC:TT=23.12, C.I.95%=[3.04,175.36]) (see Figure 2B). In 
the pathologically-confirmed AD subset (n=262), no test survived correction for multiple testing (for 
rs676759, interaction p=0.16, see Figure 2C), suggesting that the interaction effect is specific to 
individuals without confirmed AD.  
Since all interactions showed regulatory effects on the same transcript, SORL1-005, we evaluated the 
effect of SORL1-005 expression on five measures of postmortem neuropathology in the ROS/MAP 




































































increased levels of SORL1-005 were associated only with increased number of plaques SORL1-005 
(F1,428=4.91, p=0.027, n=439), though this result did not survive correction for multiple testing (see 
Supplementary Results). No effects were observed for any other pathology at praw<0.05. 
 
3.2 In Vivo Neuroimaging 
Sample demographics for ADNI subjects are summarized in Table 2. A total of 36 SNP-SNP interactions 
surviving correction for multiple testing in SORL1 expression analyses were analyzed across seven 
bilateral frontal cortical regions of interest for in vivo Aβ using [18F]Florbetapir PET, resulting in a total of 
252 significant tests before correction. After FDR correction, 44 models remained significant. Between 
these 44 models, 18 different SORL1 SNPs demonstrated significant interaction with BDNF Val66Met to 
predict levels of frontal Aβ across five regions of interest (see Supplementary Results). The top SNP 
showing interaction was rs618874 (F1,649=12.12, praw=5.3x10
-4, n=710); the rs618874T allele was 
associated with decreased amyloid burden in BDNFVal homozygotes, but increased amyloid in BDNFMet 
carriers (see Figure 3). This is in alignment with effects observed on gene expression and 
neuropathology in ROS/MAP, whereby the rs12364988T allele, which is strongly linked to rs618874T 
(ADNI r2=0.73; ROS/MAP r2=0.74), resulted in BDNFMet-dependent increases in SORL1-005. 
Structural imaging analyses revealed similar patterns of SORL1-BDNF interaction at p<0.05; however, 






































































We found that linked SORL1 variants interacted with BDNF Val66Met to regulate prefrontal expression 
of one SORL1 transcript, SORL1-005 (ENST00000534286), and that this isoform was weakly associated 
with increased diffuse amyloid plaques in midfrontal tissue from the same subjects. We then 
demonstrated that the same genetic interactions regulating SORL1-005 expression determined frontal 
amyloid deposition in vivo using PET imaging. The gene variant that most significantly interacted with 
BDNF Val66Met to influence SORL1-005 expression, rs12364988, is part of the same highly-linked 
haplotype block recently shown to interact with BDNF in human iPSC-derived neurons to regulate SORL1 
mRNA expression [8]. By combining layers of genetic, transcriptomic, and neuroimaging data, we have 
shown that BDNF Val66Met status may determine the background on which SORL1 risk variants exert 
their effects (results across phenotypes are summarized in Table S1). Through this lens, BDNF’s 
modulation of resilience via cognitive reserve [32] is also clarified; depending on SORL1 genotype, the 
effects of Val66Met may influence protection against AD by promoting diffuse plaque deposition 
preferentially over neuritic. 
SORL1 is a member of the Vps10p-domain (Vps10p-D) family of neuronal receptors [33], several of 
which have been shown to interact directly with BDNF. Sortilin, another Vps10p receptor, is responsible 
for intracellular trafficking of newly synthesized proBDNF via its physical interaction with the region of 
BDNF pro-domain in which the Val66Met substitution resides [34]. BDNF Val66Met has been associated 
with risk for AD [35] and AD-related intermediate phenotypes [36], albeit inconsistently, and is thought 
to be an important factor in modulating neuroplasciticty [10]. Our results may provide insight into the 
inconsistent literature on the effects of BDNF Val66Met (i.e. why it has not been identified by GWAS for 
AD); the vast majority of studies in this area have not accounted for SORL1 genotype and thus may be 
missing crucial information determining the direction and magnitude of BDNF’s effects. The mechanisms 




































































recently it was shown that BDNF Val66Met alters the expression of miR-146 in humanized BDNF knock-
in mice [37], suggesting that this variant may influence the expression of multiple target genes 
simultaneously. 
SORL1-005 is a putative protein-coding transcript (UniProt ID: E9PP43) of 3 501bp, containing 25 exons 
(compared to 48 in the full length transcript), and lacking the Vps10p domain found in full length SORL1 
protein. The lack of this domain could potentially interrupt the function of SORL1-005 protein within the 
amyloid cascade and contribute to the accumulation of pathogenic Aβ species [3], consistent with our 
observations of concomitant increases in diffuse plaques postmortem and amyloid burden in vivo. A 
second mechanism via which increased SORL1-005 may exert pathological effects on brain structure is 
regulated intramembrane proteolysis [38]; SORL1 has been shown to undergo sequential cleavage by 
alpha and gamma-secretase enzymes [39], liberating protein fragments that are internalized to the 
nucleus and play roles in gene regulation. It is possible that altered recognition of SORL1-005 by gamma-
secretase results in the absence of SORL1 COOH-terminal fragments that may preserve pathologically-
protective gene regulation; such absence is also seen in cells co-transfected with FAD-linked PS1 
mutations [39]. In either case, given SORL1’s dual roles in recycling APP [3] and lysosomal targeting of 
Aβ [40], alternative splicing causing loss-of-function would be expected to influence amyloid levels in 
the direction observed in our study.  
While functional annotations of SORL1 variants within our top interacting SORL1 haplotype block (which 
lie approximately 50kb 5’ exon 25 of the full length transcript; Figure S4) do not directly reveal an 
underlying mechanism related to alternative splicing (See Supplementary Materials), it has been shown 
that a functional SORL1 rare variant (rs117260922, E270K), which is located only one base pair from our 




































































interact with APP at the cell surface [41]. In addition, another nearby variant in high LD with rs12364988 
– rs923893 – is a cis-eQTL for SORL1 expression in human brain tissue [42]. 
Our observation that SORL1-BDNF interactions influenced SORL1-005 expression in non-pathological AD 
subjects may be due to the interruption or masking of transcriptional mechanisms by AD-related 
neuropathology: it has been shown that Aβ oligomers are capable of inducing gene expression changes 
across diverse functional classes in human brain tissue [43], and that genes involved in intracellular 
trafficking specifically show marked down-regulation in postmortem AD brain [44]. These findings may 
have implications for identifying gene regulatory mechanisms in AD brain, as the effects of 
transcriptional machinery may be altered depending on levels of cellular pathology. 
The weak association of SORL1-005 with only diffuse plaques of midfrontal cortex may suggest a 
differential contribution of the SORL1-BDNF interaction to diffuse vs. neuritic plaque pathology. Diffuse 
plaques account for the majority of plaque pathology in human brain [45], are associated with AD 
diagnosis [46], but are also found frequently in so-called “normal” aging [47], suggesting that they may 
be indicative of the early, pre-symptomatic stages of disease or even just a non-pathological form of 
aging. It has been shown that Aβ plays crucial roles in neuroplasticity [48], and may be produced as part 
of a neuroprotective response to synaptic pathology in AD [49]; Aβ1-28 has been shown to promote 
growth and survival of hippocampal neurons [50]. As a result, it is possible that the regulatory action of 
SORL1 and BDNF may act on amyloid pathways in such a way that influences both neuritic plaque 
(neurotoxic) and diffuse plaque (neuroprotective) pathologies. Particularly, the interactive effects of 
variants identified by our study may influence the latter pathway to the greatest degree; hence why 
genetic effects are only observed in the non-AD group. Further, [18F]Florbetapir has been shown to 
measure both neuritic and diffuse plaque burden in the brain [51], meaning that our in vivo Aβ findings 




































































together, we suggest that the interaction between BDNF and SORL1 may provide links between AD risk 
and the healthy aging process by influencing the expression of a transcript that is not related to AD risk, 
but nonetheless modulates diffuse amyloid deposition postmortem and in vivo.  
The present study has several limitations. First, the decision to analyze gene expression as a binary 
outcome necessarily introduces a level of bias into the analyses; it is possible that by splitting the 
distributions of transcript expression into expressed vs. not expressed, we missed quantitative 
information that here we would have been unable to test without violating statistical assumptions. 
Second, the expression of SORL1 has been shown to be cell-type specific [52], whereby some individuals 
with AD have loss of expression in neurons, but not glia. We are unable to test this directly in our 
sample, as the ROS/MAP expression data are derived from tissue homogenate of the prefrontal cortex. 
We took steps to maintain regional specificity in our analyses by analyzing frontal pathology, which 
should help mitigate some concerns over differences between regions. Third, as with any RNA 
sequencing experiment, alignment error must be considered as a potential confounder. Fourth, BDNF’s 
effects on amyloid pathology [8] as well as TrkB-dependeng trophic signaling [14] have been shown to 
depend on SORL1, and in this study we used the functional Val66Met variant as an indirect proxy for 
brain BDNF activity [9]. However, due to inconsistency in the literature surrounding the influence of 
Val66Met on BDNF protein and mRNA expression in blood and brain tissue, we acknowledge the 
uncertainty in this assumption. Finally, we acknowledge that mRNA levels of SORL1 may not be reliable 
indicators of protein levels. Unfortunately, we did not measure protein directly in our experiments. 
Future studies will need to measure protein directly in the tissues.  In fact, proteomic projects are 
currently underway in the ROS/MAP cohort that will include both SORL1 and BDNF. However, there are 




































































modifications. Thus, ultimately, a variety of approaches, including the mRNA approach used in the 
present study, are useful for identifying genes and proteins important in the pathogenesis of AD. 
In conclusion, we have demonstrated a novel interaction between two AD-associated genes that 
determines the isoform-specific expression of SORL1, and impacts levels of amyloid deposition in two 
large samples. We believe that this interaction may provide insight into the convergence of prototypical 
neurotoxic Aβ deposition and the brain reserve found in aged individuals who are resilient to AD. This 
work has implications for the way that genetic association studies of SORL1 and BDNF are interpreted 
and may be of use in determining specific groups of genetically at-risk individuals in future clinical trials 
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Figure 1. –Log(p-values) for interaction terms of SNPs across the SORL1 locus with BDNF Val66Met in 
logistic regression models for expression of SORL1-005 (ENST00000534286). The top interacting SNP 
was rs12364988 (Wald X21=19.09, p=1.25x10
-5, n=441). Colour coding shows LD structure in the region 
(according to 1000 Genomes hg19 EUR reference), with red indicating high LD (r2>0.8) and dark blue 
indicating low LD (r2<0.2) with respect to rs12364988. Plot was generated with LocusZoom [53]. 
Figure 2. Top interaction effects of SORL1 variants (rs12364988 and rs676759) and BDNF Val66Met on 
prefrontal mRNA expression of SORL1-005 (ENST00000534286) in A) the whole ROS/MAP sample (Wald 
X21=19.09, p=1.25x10
-5, n=441), B) only non-pathologically confirmed AD (non-pathoAD) subjects (Wald 
X21=19.27, p=1.14x10
-5, n=179), and C) pathologically confirmed AD (pathoAD) subjects (Wald X21=1.99, 
p=0.16, n=262). 
Figure 3. SORL1-BDNF interaction effect on in vivo Aβ in the pars orbitalis measured by [18F]Florbetapir 
PET in the ADNI 2 sample (n=710). A) Residual amyloid load according to SORL1 rs618874 and BDNF 
Val66Met groups. B) Effect of SORL1 rs618874 within BDNFVal homozygote and BDNFMet carrier groups 
separately, adjusted for co-variates, with 95% confidence intervals. Rs618874T was associated with 
decreased amyloid burden in BDNFVal homozygotes (ΔAβTT:CC=-0.067, C.I.95%= [-0.13,-0.01]), but increased 
amyloid in BDNFMet carriers (ΔAβTT:CC=0.12, C.I.95%= [0.03,0.21]). Results were not impacted by removal of 






































































Table 1. ROS/MAP Sample Demographics 




   
Sex (F/M) 107 F, 72 M 171 F, 91 M 0.027   
Age at death (y(SD)) 86.6 (7.2) 89.8 (5.9) <0.0001   
Education (y(SD)) 16.3 (3.6) 16.6 (3.4) 0.47   
MMSE (SD) 25.1 (6.8) 19.1 (9.4) <0.0001   
RIN (SD) 7.2 (1.0) 7.1 (0.9) 0.21   
PMI (SD) 6.8 (4.1) 7.3 (5.4) 0.25   
APOE ε4 status (-/+) 153-, 26+ (15%+) 168-, 94+ 
(36%+) 
<0.0001   
BDNF genotype (valval/met 
carrier) 
116Val, 63M 170Val, 92M 1   







Sex (F/M) 81 F, 31 M 30 F, 11 M 12 F, 1 M 3 F, 3 M 0.25 
Age at scan (y(SD)) 83.3 (6.7) 85.3 (5.1) 85.8 (3.8) 86 (2.8) 0.072 
Education (y(SD)) 15.6 (3.3) 15.22 (3.1) 15.9 (2.4) 14.7 (2.4) 0.82 
MMSE (SD) 28.3 (1.5) 26.9 (2.1) 19.2 (6) 22.7 (4.5) <0.0001 







BDNF genotype (valval/met 
carrier) 
77/35 29/12 7/6 4/2 0.81 
Note: 
1
p-values are two-sided and derived from Fisher’s exact test (for sex, APOE ε4 status, and BDNF genotype) 
and either two-sample t-tests (in expression dataset for age at death, education, MMSE, RIN, and PMI) or ANOVA 
(in imaging dataset for age at scan, education, and MMSE). ROS/MAP = Religious Orders Study / Memory and 
Aging Project; CN = cognitively normal; non-AD = non-neuropathologically-confirmed Alzheimer’s disease; pathoAD 
= neuropathologically-confirmed Alzheimer’s disease; MMSE = Mini Mental Status Exam score at last visit before 
death; Val = Val/Val homozygotes; Met = Met allele carriers; F = female; M = male; y = years; SD = standard 





































































Table 2. ADNI Sample Demographics 
ADNI 1/GO/2 MRI (n=1 
285) 





Study phase (1, GO, 2) 193 (1), 142 
(2) 
82 (2) 111 (GO), 124 
(2) 
291 (1), 116 
(2) 
131 (1), 95 
(2) 
<0.0001 
Sex (F/M) 159 F, 176 M 51 F, 31 M 101 F, 134 M 155 F, 252 M 102 F, 124 
M 
0.0012 
Age (y(SD)) 74.7 (5.4) 71.7 (5.4) 71.0 (7.1) 73.3 (7.4) 74.3 (8.1) <0.0001 
Education (y(SD)) 16.2 (2.7) 16.7 (2.6) 16.1 (2.6) 15.8 (2.9) 15.2 (2.9) <0.0001 
MMSE (SD) 29 (1.1) 29 (1.2) 28.4 (1.6) 27.1 (1.8) 23.1 (2.1) <0.0001 













231/104 54/28 159/76 271/136 154/72 0.96 
ADNI GO/2 Amyloid 
Sample (n=710) 





Study phase (GO, 2) 136 (2) 88 (2) 106 (GO), 138 
(2) 
121 (2) 121 (2) <0.0001 
Sex (F/M) 66 F, 70 M 55 F, 33 M 107 F, 137 M 55 F, 66 M 50 F, 71 M 0.024 
Age (y(SD)) 73.9 (5.9) 72.2 (5.8) 71.4 (7.4) 72.5 (7.5) 74.3 (8.5) 0.001 
Education (y(SD)) 16.5 (2.5) 16.8 (2.6) 16 (2.6) 16.5 (2.6) 15.8 (2.6) 0.016 
MMSE (SD) 29.1 (1.2) 29 (1.3) 28.3 (1.6) 27.7 (1.8) 23.1 (2.1) <0.0001 













95/41 58/30 167/77 89/32 79/42 0.66 
Note: *p-values are two-sided and derived from Fisher’s exact test (for study phase, sex, APOE ε4 status, and BDNF 
genotype) and ANOVA (for age, education, and MMSE). ADNI = Alzheimer’s Disease Neuroimaging Initiative; CN = 
cognitively normal; SMC = some memory concern; EMCI; early mild cognitive impairment; LMCI = late mild 
cognitive impairment; AD = Alzheimer’s disease; MMSE = Mini Mental Status Exam score; Val = Val/Val 
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 BDNF Val66Met interacts with SORL1 variants to impact expression of SORL1-005. 
 SORL1-005 may influence diffuse rather than neuritic amyloid pathology in postmortem brain. 
 The BDNF-SORL1 interaction effect is present in individuals without confirmed Alzheimer’s 
disease. 






INTRODUCTION: The brain-derived neurotrophic factor (BDNF) interacts with important genetic 
Alzheimer’s disease (AD) risk factors. Specifically, variants within the SORL1 gene determine BDNF’s 
ability to reduce Aβ in vitro. We sought to test whether functional BDNF variation interacts with SORL1 
genotypes to influence expression and downstream AD-related processes in humans. 
METHODS: We analyzed postmortem brain RNA-sequencing and neuropathological data for 441 
subjects from the Religious Orders Study/Memory and Aging Project, and molecular and structural 
neuroimaging data for 1 285 subjects from the Alzheimer’s Disease Neuroimaging Initiative. 
RESULTS: We found one SORL1 RNA transcript strongly regulated by SORL1-BDNF interactions in elderly 
without pathological AD, and showing stronger associations with diffuse than neuritic Aβ plaques. The 
same SORL1-BDNF interactions also significantly influenced Aβ load as measured with [18F]Florbetapir 
PET.  
DISCUSSION: Our results bridge the gap between risk and resilience factors for AD, demonstrating 
interdependent roles of established SORL1 and BDNF functional genotypes. 
 




Genetic epistasis may be a major contributor to the “missing heritability” of late-onset Alzheimer’s 
disease (AD) [1], and recent efforts have demonstrated the importance of evaluating gene-gene 
interactions among AD risk variants using integrative approaches [2]. Variants within the sortilin-related 
receptor (SORL1, SORLA, LR11) gene are among the most highly-replicated genetic risk factors for late-
onset Alzheimer’s disease (AD); they have been associated with AD diagnosis in candidate studies [3], 
genome-wide association studies [4], and meta-analyses [5]. While studies have implicated SORL1 
genotypes independently in gene expression [6], the transcriptional control of SORL1 also depends on 
extragenous factors, particularly levels of the brain-derived neurotrophic factor (BDNF) [7]. Accordingly, 
it was recently shown that BDNF administration in iPSC-derived neuron cultures up-regulates SORL1 
expression in a SORL1-genotype dependent manner [8]. The BDNF Val66Met polymorphism determines 
the activity-dependent secretion of BDNF [9] and also the function of the BDNF pro-peptide in 
facilitating neuroplasticity (LTD) [10]. As such, BDNF Val66Met may serve as a functional assay for BDNF 
activity in the brain. Effects of BDNF Val66Met have been shown on early AD phenotypes, such as 
structural [11] and functional [12] neuroimaging, and cognition [13]. These effects may be downstream 
consequences of BDNF’s stimulation of SORL1 activity [14], and therefore may be subject to modulation 
by both BDNF and SORL1 genotypes interdependently. Studying the interaction of functional BDNF and 
SORL1 genotypes in large, well-characterized samples may provide insight into the nature of this 
transcriptional regulatory mechanism and risk vs. resilience for AD. 
We have previously shown a main effect of SORL1 genotype on levels of prefrontal SORL1 mRNA in 
postmortem brain [15] using microarray technology that was unable to detect specific SORL1 transcript 
isoforms. Since previous reports show differential SORL1 transcript expression both in AD [16] and as a 
result of SORL1 genotype [6], microarray analyses may have missed crucial transcript-specific 
information. RNA-sequencing (RNA-seq) offers distinct advantages over probe-based methodologies as 
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it allows for the alignment of assembled transcript reads to any sequence template and the estimation 
of isoform expression based on these reads. We have also previously shown age-dependent effects of 
the BDNF Val66Met polymorphism on white matter microstructure, cortical thickness, and episodic 
memory performance in healthy adults [17], suggesting that as-of-yet unidentified factors may act to 
influence BDNF’s protective effects on neurodegeneration and cognitive aging. 
Given the regulatory interaction of BDNF protein with SORL1 genotype in human iPSC-derived neurons 
[8], we hypothesized that common SORL1 gene variants may interact with BDNF Val66Met to influence 
the expression of SORL1 transcripts. Further, given the functions of SORL1 within the amyloidogenic 
cascade, we hypothesized that genetic interactions predicting altered SORL1 expression may affect 
amyloid neuropathology as well as brain structures at risk in the early stages of AD. To test this, we 
performed an unbiased locus-wide gene-gene interaction analysis of SORL1 SNPs with BDNF Val66Met 
to model the expression of multiple SORL1 transcripts, quantified by RNA-seq of postmortem brain 
tissue, in 441 subjects from the Religious Orders Study and Memory and Aging Project (ROS/MAP). 
Transcripts showing significant evidence for regulation by SORL1-BDNF interactions were also tested for 
effects on postmortem neuropathology in the same subjects. We then tested significant SNP-SNP 
interactions for effects on in vivo frontal amyloid load, as measured by [18F]Florbetapir PET, in 710 
subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Finally, to explore potential 
downstream effects of these SNP-SNP interactions on brain structure, we examined 1 285 subjects from 
ADNI and 172 subjects from ROS/MAP with MRI estimates of entorhinal cortex volume, and 185 subjects 





2.1 Religious Orders Study and Memory and Aging Project (ROS/MAP) 
2.1.1 Study Participants 
A total of 441 subjects with genomic, RNA sequencing, and neuropathological data were included in the 
present study. All participants were from ROS [18] and MAP [18]; two large ongoing cohort studies 
enrolling non-AD subjects at baseline, centered at the Rush Alzheimer’s Disease Center at Rush 
University in Chicago, IL. Both studies were approved by the Institutional Review Board of Rush 
University Medical Center.  
2.1.2 Genetics 
Genotyping of all subjects was performed using the Affymetrix (Santa Clara, CA, USA) Genechip 6.0 
platform. APOE (rs7412 and rs429358) genotypes were imputed from MACH (version 1.0.16a) and 
HapMap release 22 CEU (build 36), as previously described [19]. Common variants within 10kb of the 
SORL1 locus (chr. 11, position 121,312,912 – 121,514,471; GRCh37 coordinates) were extracted using 
PLINK (v1.90b) [20]. Variants were pruned for minor allele frequency (MAF>0.1) and Hardy-Weinberg 
Equilibrium (HWE p>0.001), resulting in a final set of 160 for analysis.  
2.1.3 Postmortem SORL1 Isoform Expression 
RNA-seq data (50 million paired-end reads of 101 bp) were generated from frozen dorsolateral 
prefrontal cortex tissues following the construction of complementary DNA libraries, as previously 
published [21]. Expression abundance was calculated as fragments per kilobase of exon per million reads 
mapped (FPKM) (See Supplementary Methods). 
2.1.4 Postmortem Neuropathology 
A board-certified neuropathologist blinded to age and all clinical data established neuropathologic 
diagnoses for each subject. Five types of AD pathology were quantified for ROS/MAP subject samples: 
7 
 
mid-frontal neuritic plaques and diffuse plaques, total amyloid, paired helical filament tau, and 
neurofibrillary tangles (see supplementary Methods). 
2.1.5 In Vivo Structural MRI 
High resolution structural T1 images were acquired for a subset of n=172 ROS/MAP subjects (overlap of 
n=5 with subjects from expression dataset) [22] and entorhinal cortex volumes (mm3) were estimated 
for each subject using Freesurfer (http://surfer.nmr.mgh.harvard.edu) (see Supplementary Methods). 
 
2.2 Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
2.2.1 Study Participants 
The Alzheimer’s Disease Neuroimaging Initiative (ADNI; phases 1, GO, and 2 – see Supplementary 
Methods) is a multi-center collaboration enrolling elderly subjects at various stages of cognitive 
impairment. All subjects are administered clinical evaluations at time of study enrollment by trained 
physicians as previously described [23]. See supplementary Methods for details. 
2.2.2 Genetics 
ADNI subjects were genotyped using the HumanOmniExpress BeadChip (Illumina Inc., San Diego, CA). 
Genetic quality control was conducted using PLINK (v1.90b). Imputation was performed using IMPUTE2 
(v2.3.1) [24], with the 1000 Genomes Phase1 integrated haplotypes as the reference panel. SNPs with 
an IMPUTE2 info score of less than 0.5, HWE p<0.001, and MAF <0.01 were excluded from further 
analyses.  
2.2.3 In Vivo Structural MRI and DTI 
A total of 1 285 subjects from ADNI 1, GO, and 2 underwent structural MRI protocols to generate 
estimates of entorhinal cortex volume. Entorhinal cortex and total intracranial volumes were estimated 
using FreeSurfer (v4.3) [25]. Diffusion-weighted images were acquired for a subset of 185 subjects from 
ADNI 2 using an optimized protocol and rigorous quality control [26]. Estimates of fractional anisotropy 
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(FA) were generated for specific white matter tracts according to the JHU “Eve” white matter atlas labels 
(see Supplementary Methods).  
2.2.4 In Vivo Aβ [18F]Florbetapir PET 
PET imaging data were available for 710 subjects from ADNI 2. Details of brain Aβ [18F]Florbetapir PET 
imaging and preprocessing in ADNI have been described elsewhere [27]. Signal from [18F]Florbetapir 
within cortical subregions were not standardized and so we co-varied for signal from a composite 
reference region (see Supplementary Methods). 
 
2.3 Statistical Analysis 
Analyses were performed using R (v3.1.1) statistical software (http://www.r-project.org/) [28]. 
Haploview (v4.2) [29] was used for calculations of LD structure. Based on lack of expression, data for 
three transcripts could not be analyzed: SORL1-003, SORL1-004, SORL1-007 (See Figure S1 for size and 
position of all transcripts). All 10 remaining transcripts showed heavily right-skewed FPKM distributions 
(skewness ranging from 0.71-5.3, all D’Agostino test p<1.3x10-5) that could not be coerced to normal 
(using Box-Cox power transformations) and thus were evaluated as binary outcomes (expressed above 0 
FPKM vs. 0 FPKM, or median split where the median>0). Each of 160 SNPs within the SORL1 locus were 
tested for interaction with BDNF Val66Met, with each transcript as outcome using logistic regression, 
co-varying for technical and demographic factors. 
To correct for multiple testing accounting for LD structure across SORL1 SNPs, we first calculated the 
effective number of independent SNPs across the SORL1 locus (as in Replogle et al. [30]); of the 160 
SORL1 tested, six independent SNPs captured the haplotypic diversity at this locus (strong LD structure 
shown in Figure S2). Considering 10 SORL1 transcripts, the final experiment-wise Bonferroni corrected 
significance threshold was p<8.33x10-4 (α=0.05 / 6 independent SNPs / 10 transcripts).  
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Transcripts that showed significant evidence for interactive regulation by SORL1 variants and BDNF 
Val66Met were analyzed for effects on neuropathology. Pathology levels were square-root transformed 
and analyzed using linear regression, and, since SORL1-005 expression was evaluated as a continuous 
predictor, influential observations (evaluated using dfbetas and Cook’s distance) were removed from 
these analyses (final n=439).  
SNP-SNP interactions from expression analyses that remained significant after correction for multiple 
testing were carried forward to test for effects on in vivo Aβ [18F]Florbetapir PET. To maintain regional 
specificity, average amyloid loads across seven bilateral frontal cortical regions of interest were analyzed 
as outcomes for each gene-gene interaction using linear regression. Interaction p-values were corrected 
for multiple testing using the False Discovery Rate (FDR) procedure (q=0.05).  
Finally, to examine potential downstream consequences of altered amyloid pathology on brain 
structure, the same set of SNP-SNP interactions identified by expression analyses were explored for 
effects on entorhinal cortex volume (one of the earliest brain regions to be affected by AD pathological 
lesions and atrophy [31]), and white matter FA across five bilateral tracts. 






3.1 SORL1 Transcript Expression and Postmortem Neuropathology 
Sample demographics for ROS/MAP are summarized in Table 1. Out of a total 1 600 tests, 36 remained 
significant after correction for multiple testing and all of these 36 modeled the same transcript, SORL1-
005 (ENST00000534286), as the outcome (Figure 1). The SNP showing the strongest interaction effect 
with BDNF Val66Met was rs12364988 (Wald X21=19.09, p=1.25x10
-5, n=441), where the rs12364988T 
allele reduced likelihood of SORL1-005 expression in the BDNFVal homozygotes (ORTT:CC=0.38, 
C.I.95%=[0.18,0.80]), but greatly increased likelihood of expression among BDNF
Met carriers (ORTT:CC=7.03, 
C.I.95%=[2.42,20.46]) (see Figure 2A). Rs12364988, within the 5’ region of SORL1, was in moderate to 
strong linkage disequilibrium (LD) with the remaining 35 SNPs that showed significant interaction with 
BDNF Val66Met in the ROS/MAP sample (D’ range=0.80-1, r2 range=0.35-1).  
Post-hoc tests in diagnostic subgroups revealed different patterns of effect in non-AD vs. pathologically-
confirmed AD subjects. In the non-AD subgroup (n=179), 44 tests showed interaction p-values below our 
threshold for multiple testing. As in the overall sample, all significant models predicted SORL1-005 
expression as outcome, though with much stronger effect sizes observed for the top interacting SORL1 
SNP (rs676759, Wald X21=19.27, p=1.14x10
-5) in the BDNFVal homozygote (ORCC:TT=0.093, 
C.I.95%=[0.026,0.34]) and BDNF
Met carrier groups (ORCC:TT=23.12, C.I.95%=[3.04,175.36]) (see Figure 2B). In 
the pathologically-confirmed AD subset (n=262), no test survived correction for multiple testing (for 
rs676759, interaction p=0.16, see Figure 2C), suggesting that the interaction effect is specific to 
individuals without confirmed AD.  
Since all interactions showed regulatory effects on the same transcript, SORL1-005, we evaluated the 
effect of SORL1-005 expression on five measures of postmortem neuropathology in the ROS/MAP 
sample. Across diagnostic groups, there was a modest effect of SORL1-005 on diffuse plaques, whereby 
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increased levels of SORL1-005 were associated only with increased number of plaques SORL1-005 
(F1,428=4.91, p=0.027, n=439), though this result did not survive correction for multiple testing (see 
Supplementary Results). No effects were observed for any other pathology at praw<0.05. 
 
3.2 In Vivo Neuroimaging 
Sample demographics for ADNI subjects are summarized in Table 2. A total of 36 SNP-SNP interactions 
surviving correction for multiple testing in SORL1 expression analyses were analyzed across seven 
bilateral frontal cortical regions of interest for in vivo Aβ using [18F]Florbetapir PET, resulting in a total of 
252 significant tests before correction. After FDR correction, 44 models remained significant. Between 
these 44 models, 18 different SORL1 SNPs demonstrated significant interaction with BDNF Val66Met to 
predict levels of frontal Aβ across five regions of interest (see Supplementary Results). The top SNP 
showing interaction was rs618874 (F1,649=12.12, praw=5.3x10
-4, n=710); the rs618874T allele was 
associated with decreased amyloid burden in BDNFVal homozygotes, but increased amyloid in BDNFMet 
carriers (see Figure 3). This is in alignment with effects observed on gene expression and 
neuropathology in ROS/MAP, whereby the rs12364988T allele, which is strongly linked to rs618874T 
(ADNI r2=0.73; ROS/MAP r2=0.74), resulted in BDNFMet-dependent increases in SORL1-005. 
Structural imaging analyses revealed similar patterns of SORL1-BDNF interaction at p<0.05; however, 





We found that linked SORL1 variants interacted with BDNF Val66Met to regulate prefrontal expression 
of one SORL1 transcript, SORL1-005 (ENST00000534286), and that this isoform was weakly associated 
with increased diffuse amyloid plaques in midfrontal tissue from the same subjects. We then 
demonstrated that the same genetic interactions regulating SORL1-005 expression determined frontal 
amyloid deposition in vivo using PET imaging. The gene variant that most significantly interacted with 
BDNF Val66Met to influence SORL1-005 expression, rs12364988, is part of the same highly-linked 
haplotype block recently shown to interact with BDNF in human iPSC-derived neurons to regulate SORL1 
mRNA expression [8]. By combining layers of genetic, transcriptomic, and neuroimaging data, we have 
shown that BDNF Val66Met status may determine the background on which SORL1 risk variants exert 
their effects (results across phenotypes are summarized in Table S1). Through this lens, BDNF’s 
modulation of resilience via cognitive reserve [32] is also clarified; depending on SORL1 genotype, the 
effects of Val66Met may influence protection against AD by promoting diffuse plaque deposition 
preferentially over neuritic. 
SORL1 is a member of the Vps10p-domain (Vps10p-D) family of neuronal receptors [33], several of 
which have been shown to interact directly with BDNF. Sortilin, another Vps10p receptor, is responsible 
for intracellular trafficking of newly synthesized proBDNF via its physical interaction with the region of 
BDNF pro-domain in which the Val66Met substitution resides [34]. BDNF Val66Met has been associated 
with risk for AD [35] and AD-related intermediate phenotypes [36], albeit inconsistently, and is thought 
to be an important factor in modulating neuroplasciticty [10]. Our results may provide insight into the 
inconsistent literature on the effects of BDNF Val66Met (i.e. why it has not been identified by GWAS for 
AD); the vast majority of studies in this area have not accounted for SORL1 genotype and thus may be 
missing crucial information determining the direction and magnitude of BDNF’s effects. The mechanisms 
via which BDNF Val66Met influences downstream risk for AD are complex and not yet understood; 
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recently it was shown that BDNF Val66Met alters the expression of miR-146 in humanized BDNF knock-
in mice [37], suggesting that this variant may influence the expression of multiple target genes 
simultaneously. 
SORL1-005 is a putative protein-coding transcript (UniProt ID: E9PP43) of 3 501bp, containing 25 exons 
(compared to 48 in the full length transcript), and lacking the Vps10p domain found in full length SORL1 
protein. The lack of this domain could potentially interrupt the function of SORL1-005 protein within the 
amyloid cascade and contribute to the accumulation of pathogenic Aβ species [3], consistent with our 
observations of concomitant increases in diffuse plaques postmortem and amyloid burden in vivo. A 
second mechanism via which increased SORL1-005 may exert pathological effects on brain structure is 
regulated intramembrane proteolysis [38]; SORL1 has been shown to undergo sequential cleavage by 
alpha and gamma-secretase enzymes [39], liberating protein fragments that are internalized to the 
nucleus and play roles in gene regulation. It is possible that altered recognition of SORL1-005 by gamma-
secretase results in the absence of SORL1 COOH-terminal fragments that may preserve pathologically-
protective gene regulation; such absence is also seen in cells co-transfected with FAD-linked PS1 
mutations [39]. In either case, given SORL1’s dual roles in recycling APP [3] and lysosomal targeting of 
Aβ [40], alternative splicing causing loss-of-function would be expected to influence amyloid levels in 
the direction observed in our study.  
While functional annotations of SORL1 variants within our top interacting SORL1 haplotype block (which 
lie approximately 50kb 5’ exon 25 of the full length transcript; Figure S4) do not directly reveal an 
underlying mechanism related to alternative splicing (See Supplementary Materials), it has been shown 
that a functional SORL1 rare variant (rs117260922, E270K), which is located only one base pair from our 
top SNP, rs12364988, is responsible for a conformational change in SORL1 that results in failure to 
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interact with APP at the cell surface [41]. In addition, another nearby variant in high LD with rs12364988 
– rs923893 – is a cis-eQTL for SORL1 expression in human brain tissue [42]. 
Our observation that SORL1-BDNF interactions influenced SORL1-005 expression in non-pathological AD 
subjects may be due to the interruption or masking of transcriptional mechanisms by AD-related 
neuropathology: it has been shown that Aβ oligomers are capable of inducing gene expression changes 
across diverse functional classes in human brain tissue [43], and that genes involved in intracellular 
trafficking specifically show marked down-regulation in postmortem AD brain [44]. These findings may 
have implications for identifying gene regulatory mechanisms in AD brain, as the effects of 
transcriptional machinery may be altered depending on levels of cellular pathology. 
The weak association of SORL1-005 with only diffuse plaques of midfrontal cortex may suggest a 
differential contribution of the SORL1-BDNF interaction to diffuse vs. neuritic plaque pathology. Diffuse 
plaques account for the majority of plaque pathology in human brain [45], are associated with AD 
diagnosis [46], but are also found frequently in so-called “normal” aging [47], suggesting that they may 
be indicative of the early, pre-symptomatic stages of disease or even just a non-pathological form of 
aging. It has been shown that Aβ plays crucial roles in neuroplasticity [48], and may be produced as part 
of a neuroprotective response to synaptic pathology in AD [49]; Aβ1-28 has been shown to promote 
growth and survival of hippocampal neurons [50]. As a result, it is possible that the regulatory action of 
SORL1 and BDNF may act on amyloid pathways in such a way that influences both neuritic plaque 
(neurotoxic) and diffuse plaque (neuroprotective) pathologies. Particularly, the interactive effects of 
variants identified by our study may influence the latter pathway to the greatest degree; hence why 
genetic effects are only observed in the non-AD group. Further, [18F]Florbetapir has been shown to 
measure both neuritic and diffuse plaque burden in the brain [51], meaning that our in vivo Aβ findings 
may be reflective of SORL1-005’s effect on diffuse plaques in postmortem frontal cortex. Taken 
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together, we suggest that the interaction between BDNF and SORL1 may provide links between AD risk 
and the healthy aging process by influencing the expression of a transcript that is not related to AD risk, 
but nonetheless modulates diffuse amyloid deposition postmortem and in vivo.  
The present study has several limitations. First, the decision to analyze gene expression as a binary 
outcome necessarily introduces a level of bias into the analyses; it is possible that by splitting the 
distributions of transcript expression into expressed vs. not expressed, we missed quantitative 
information that here we would have been unable to test without violating statistical assumptions. 
Second, the expression of SORL1 has been shown to be cell-type specific [52], whereby some individuals 
with AD have loss of expression in neurons, but not glia. We are unable to test this directly in our 
sample, as the ROS/MAP expression data are derived from tissue homogenate of the prefrontal cortex. 
We took steps to maintain regional specificity in our analyses by analyzing frontal pathology, which 
should help mitigate some concerns over differences between regions. Third, as with any RNA 
sequencing experiment, alignment error must be considered as a potential confounder. Fourth, BDNF’s 
effects on amyloid pathology [8] as well as TrkB-dependeng trophic signaling [14] have been shown to 
depend on SORL1, and in this study we used the functional Val66Met variant as an indirect proxy for 
brain BDNF activity [9]. However, due to inconsistency in the literature surrounding the influence of 
Val66Met on BDNF protein and mRNA expression in blood and brain tissue, we acknowledge the 
uncertainty in this assumption. Finally, we acknowledge that mRNA levels of SORL1 may not be reliable 
indicators of protein levels. Unfortunately, we did not measure protein directly in our experiments. 
Future studies will need to measure protein directly in the tissues.  In fact, proteomic projects are 
currently underway in the ROS/MAP cohort that will include both SORL1 and BDNF. However, there are 
also limitations to targeted proteomics; for example, it cannot capture individual post-translational 
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modifications. Thus, ultimately, a variety of approaches, including the mRNA approach used in the 
present study, are useful for identifying genes and proteins important in the pathogenesis of AD. 
In conclusion, we have demonstrated a novel interaction between two AD-associated genes that 
determines the isoform-specific expression of SORL1, and impacts levels of amyloid deposition in two 
large samples. We believe that this interaction may provide insight into the convergence of prototypical 
neurotoxic Aβ deposition and the brain reserve found in aged individuals who are resilient to AD. This 
work has implications for the way that genetic association studies of SORL1 and BDNF are interpreted 
and may be of use in determining specific groups of genetically at-risk individuals in future clinical trials 
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Figure 1. –Log(p-values) for interaction terms of SNPs across the SORL1 locus with BDNF Val66Met in 
logistic regression models for expression of SORL1-005 (ENST00000534286). The top interacting SNP 
was rs12364988 (Wald X21=19.09, p=1.25x10
-5, n=441). Colour coding shows LD structure in the region 
(according to 1000 Genomes hg19 EUR reference), with red indicating high LD (r2>0.8) and dark blue 
indicating low LD (r2<0.2) with respect to rs12364988. Plot was generated with LocusZoom [53]. 
Figure 2. Top interaction effects of SORL1 variants (rs12364988 and rs676759) and BDNF Val66Met on 
prefrontal mRNA expression of SORL1-005 (ENST00000534286) in A) the whole ROS/MAP sample (Wald 
X21=19.09, p=1.25x10
-5, n=441), B) only non-pathologically confirmed AD (non-pathoAD) subjects (Wald 
X21=19.27, p=1.14x10
-5, n=179), and C) pathologically confirmed AD (pathoAD) subjects (Wald X21=1.99, 
p=0.16, n=262). 
Figure 3. SORL1-BDNF interaction effect on in vivo Aβ in the pars orbitalis measured by [18F]Florbetapir 
PET in the ADNI 2 sample (n=710). A) Residual amyloid load according to SORL1 rs618874 and BDNF 
Val66Met groups. B) Effect of SORL1 rs618874 within BDNFVal homozygote and BDNFMet carrier groups 
separately, adjusted for co-variates, with 95% confidence intervals. Rs618874T was associated with 
decreased amyloid burden in BDNFVal homozygotes (ΔAβTT:CC=-0.067, C.I.95%= [-0.13,-0.01]), but increased 
amyloid in BDNFMet carriers (ΔAβTT:CC=0.12, C.I.95%= [0.03,0.21]). Results were not impacted by removal of 





Table 1. ROS/MAP Sample Demographics 




   
Sex (F/M) 107 F, 72 M 171 F, 91 M 0.027   
Age at death (y(SD)) 86.6 (7.2) 89.8 (5.9) <0.0001   
Education (y(SD)) 16.3 (3.6) 16.6 (3.4) 0.47   
MMSE (SD) 25.1 (6.8) 19.1 (9.4) <0.0001   
RIN (SD) 7.2 (1.0) 7.1 (0.9) 0.21   
PMI (SD) 6.8 (4.1) 7.3 (5.4) 0.25   
APOE ε4 status (-/+) 153-, 26+ (15%+) 168-, 94+ 
(36%+) 
<0.0001   
BDNF genotype (valval/met 
carrier) 
116Val, 63M 170Val, 92M 1   







Sex (F/M) 81 F, 31 M 30 F, 11 M 12 F, 1 M 3 F, 3 M 0.25 
Age at scan (y(SD)) 83.3 (6.7) 85.3 (5.1) 85.8 (3.8) 86 (2.8) 0.072 
Education (y(SD)) 15.6 (3.3) 15.22 (3.1) 15.9 (2.4) 14.7 (2.4) 0.82 
MMSE (SD) 28.3 (1.5) 26.9 (2.1) 19.2 (6) 22.7 (4.5) <0.0001 







BDNF genotype (valval/met 
carrier) 
77/35 29/12 7/6 4/2 0.81 
Note: 
1
p-values are two-sided and derived from Fisher’s exact test (for sex, APOE ε4 status, and BDNF genotype) 
and either two-sample t-tests (in expression dataset for age at death, education, MMSE, RIN, and PMI) or ANOVA 
(in imaging dataset for age at scan, education, and MMSE). ROS/MAP = Religious Orders Study / Memory and 
Aging Project; CN = cognitively normal; non-AD = non-neuropathologically-confirmed Alzheimer’s disease; pathoAD 
= neuropathologically-confirmed Alzheimer’s disease; MMSE = Mini Mental Status Exam score at last visit before 
death; Val = Val/Val homozygotes; Met = Met allele carriers; F = female; M = male; y = years; SD = standard 




Table 2. ADNI Sample Demographics 
ADNI 1/GO/2 MRI (n=1 
285) 





Study phase (1, GO, 2) 193 (1), 142 
(2) 
82 (2) 111 (GO), 124 
(2) 
291 (1), 116 
(2) 
131 (1), 95 
(2) 
<0.0001 
Sex (F/M) 159 F, 176 M 51 F, 31 M 101 F, 134 M 155 F, 252 M 102 F, 124 
M 
0.0012 
Age (y(SD)) 74.7 (5.4) 71.7 (5.4) 71.0 (7.1) 73.3 (7.4) 74.3 (8.1) <0.0001 
Education (y(SD)) 16.2 (2.7) 16.7 (2.6) 16.1 (2.6) 15.8 (2.9) 15.2 (2.9) <0.0001 
MMSE (SD) 29 (1.1) 29 (1.2) 28.4 (1.6) 27.1 (1.8) 23.1 (2.1) <0.0001 













231/104 54/28 159/76 271/136 154/72 0.96 
ADNI GO/2 Amyloid 
Sample (n=710) 





Study phase (GO, 2) 136 (2) 88 (2) 106 (GO), 138 
(2) 
121 (2) 121 (2) <0.0001 
Sex (F/M) 66 F, 70 M 55 F, 33 M 107 F, 137 M 55 F, 66 M 50 F, 71 M 0.024 
Age (y(SD)) 73.9 (5.9) 72.2 (5.8) 71.4 (7.4) 72.5 (7.5) 74.3 (8.5) 0.001 
Education (y(SD)) 16.5 (2.5) 16.8 (2.6) 16 (2.6) 16.5 (2.6) 15.8 (2.6) 0.016 
MMSE (SD) 29.1 (1.2) 29 (1.3) 28.3 (1.6) 27.7 (1.8) 23.1 (2.1) <0.0001 













95/41 58/30 167/77 89/32 79/42 0.66 
Note: *p-values are two-sided and derived from Fisher’s exact test (for study phase, sex, APOE ε4 status, and BDNF 
genotype) and ANOVA (for age, education, and MMSE). ADNI = Alzheimer’s Disease Neuroimaging Initiative; CN = 
cognitively normal; SMC = some memory concern; EMCI; early mild cognitive impairment; LMCI = late mild 
cognitive impairment; AD = Alzheimer’s disease; MMSE = Mini Mental Status Exam score; Val = Val/Val 
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